BioPharma & Healthcare Related News

Isogenica Announces New Licence Agreement With Top-25 Global Pharmaceutical Company

Cambridge, UK | 21st February 2017. Isogenica Ltd, a leader in the design and construction of innovative and highly diverse synthetic antibody libraries, today announced a new licensing deal with a top-25 global pharmaceutical company which specialises in immunology, oncology and [...]

By | February 21st, 2017|BioPharma & Healthcare, News, Press Releases, Therapeutics|

3 Biotech Trends in 2017

Originally featured on SOSV As I start to look at the emerging trends of 2017 from the vantage of IndieBio, where we see hundreds of biotech startup applications and technologies per year, a few key themes are already emerging. Even as [...]

By | February 21st, 2017|BioPharma & Healthcare, News|

Cell Design Labs’ Scientific Founder Co-Authors Review Article Illustrating Power and Potential of Engineered Human Cells to Treat Cancer

EMERYVILLE, Calif., Feb. 09, 2017 (GLOBE NEWSWIRE) -- Cell Design Labs, Inc. today announced that its scientific founder, Wendell Lim, Ph.D., co-authored a comprehensive review article on engineered cell therapies entitled, “The Principles of Engineering Immune Cells to Treat Cancer” [...]

By | February 14th, 2017|BioPharma & Healthcare, News, Press Releases, Therapeutics|

Isogenica Announces New Licence Agreement with Maverick Therapeutics

CAMBRIDGE, England--(BUSINESS WIRE)--Isogenica Ltd, a leader in the design and construction of innovative and highly diverse synthetic antibody libraries, today announced a new licensing deal with Maverick Therapeutics, a private start-up biotechnology company utilising a proprietary T-cell engagement format for [...]

By | February 7th, 2017|BioPharma & Healthcare, News, Pharmaceuticals, Press Releases|

Meet the Speakers: Will Synthetic Biology be the Key to Our Future Health?

SynBioBeta’s fifth annual London conference is fast approaching, with leaders in industry, academia, and investment once again set to converge on Imperial College London between April 4th and 6th. A full schedule of exciting events and sessions has been lined [...]

By | February 1st, 2017|BioPharma & Healthcare, News, Pharmaceuticals, Therapeutics|

Exemplar Genetics Awarded Subcontract to Advance New Therapeutic Models for Sickle Cell Disease

SIOUX CENTER, Iowa, Jan. 26, 2017 /PRNewswire/ -- Exemplar Genetics, a wholly owned subsidiary of Intrexon Corporation (NYSE: XON) committed to enabling the study of life-threatening human diseases, has been awarded a subcontract to create genetically engineered miniswine models of sickle [...]

By | January 30th, 2017|BioPharma & Healthcare, News, Press Releases, Therapeutics|